Business Wire

PUMA

10.4.2024 10:01:29 CEST | Business Wire | Press release

Share
PUMA Launches Major Brand Campaign to Strengthen Sports Performance Positioning

Global sports company PUMA has launched its first worldwide brand campaign in 10 years “FOREVER. FASTER. - See The Game Like We Do” with the objective to strengthen PUMA’s positioning as the Fastest Sports Brand in the world. The campaign conveys the brand’s unique connection with speed and invites everyone - professional and everyday athletes alike - to see the game like PUMA does.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410842258/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Global sports company PUMA has launched its first worldwide brand campaign in 10 years “FOREVER. FASTER. - See The Game Like We Do” (Photo: Business Wire)

PUMA was founded in 1948 by Rudolf Dassler who had the vision to create shoes that make athletes agile, nimble and fast – just like a puma. Over the last 75 years, PUMA has worked with the fastest athletes, clubs and federations in the world to create cutting-edge innovations that provide sporting excellence and victories that live forever in the memories of fans across the globe.

This year – through the globally featured Brand Campaign - PUMA is demonstrating how speed has always been deeply rooted in the brand’s DNA. Speed has always been PUMA’s vantage point. The desire to be faster and overtake others is in everyone’s nature. To go faster gives you joy and an adrenaline rush like no other. The passion for speed is simply universal. “See The Game Like We Do: FOREVER. FASTER.” means to see sports and sports culture differently and ultimately win in a way only the fastest can. In a way only PUMA can. PUMA has always been able to be the first to see the next play, quick to act on its instinct, and set the pace for others to follow. This is what enables us to see the game differently, challenge conventions and create moments that will live with us forever.

“Everyone dreams of having a superpower and speed is PUMA’s,” said Arne Freundt, CEO of PUMA. “Speed is the superpower the greats use to change the game. Just like our world icons Mondo Duplantis, Karsten Warholm, Neymar Jr or Breanna Stewart, we know that speed unlocks athletic performance and victory in everyone. Through our ability to bring speed to life, PUMA invites all people to break through their own limits, unlock their personal best and become a better version of themselves, allowing them to see the game like we do: FOREVER. FASTER.”

“Our new global brand campaign is PUMA’s biggest marketing investment ever,” said Richard Teyssier, Vice President Brand and Marketing. “It is the first time that PUMA has one single message – FOREVER. FASTER. - throughout the entire year and across all performance categories such as Football, Running, Basketball and Handball. The holistic brand message is emotional and distinctive to make sure it connects and resonates with our target consumers.”

“FOREVER. FASTER. - See The Game Like We Do” launches on April 10 and will be communicated across the entire media mix, such as Social Media, TV, PR, Out Of Home Media and Points of Sale worldwide. It will include a hero brand film and supporting creative assets with featured top athletes, such as Antoine Griezmann, Breanna Stewart, Christian Pulisic, Felix Streng, Jack Grealish, Javier “Chicharito” Hernández, Karsten Warholm, Kai Havertz, Lamelo Ball, Luis Suarez, Memphis Depay, Mondo Duplantis, Neymar Jr., Sergio Aguero, Shericka Jackson, Yaroslava Mahuchikh and many others. Later this year, PUMA will present dedicated brand videos and creative assets for The CONMEBOL Copa America, UEFA Euro 2024, and The 2024 Summer Olympics.

Brand film, long version: https://youtu.be/LRJP140fv3E

Brand film, short version: https://youtu.be/OmQGUQNQkwk

Images: Link

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410842258/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye